Xeris Biopharma Holdings (NASDAQ:XERS) said it has received a US patent covering formulations in its Gvoke product line used to treat severe hypoglycemia.
The patent issued by the US Patent and Trademark Office covers methods for using the formulations in treating hypoglycemia as well as manufacturing methods, the biopharma company said.
“Xeris’ strategy is to patent early and often, including through a castle/moat approach that has led to numerous filings both at the platform and product levels," said Paul R Edick, Xeris CEO in a statement.
“The addition of this new patent further strengthens our intellectual property position in the XeriSol platform portion of our portfolio and has claims that will cover the Gvoke formulation, which is in all our currently marketed Gvoke products."
Xeris's patent portfolio consists of 178 total patents globally.
Contact the author at jon.hopkins@proactiveinvestors.com